TP53 and hepatocellular carcinoma: CRISPR/Cas9: In a novel in vivo application of this therapy in HCC, CRISPR/Cas9 was used to test the hypothesis that deactivated PTEN/p53 genes in HCC promote carcinogenesis (87).